In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Vicarious Surgical (RBOT – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $2.11.
According to TipRanks, Zimmerman is a 5-star analyst with an average return of 11.4% and a 50.20% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as PROCEPT BioRobotics, Integra Lifesciences, and Staar Surgical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vicarious Surgical with a $7.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $4.76 and a one-year low of $1.36. Currently, Vicarious Surgical has an average volume of 369.9K.
Based on the recent corporate insider activity of 126 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RBOT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
D8 Holdings Corp is a blank check company.
Read More on RBOT:
